Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZAVICONT: Continuous vs Intermittent Ceftazidime/Avibactam in Critically Ill Patients
NCT06811727Phase 4Recruiting
- Start
- Aug 2025
- Primary completion
- May 2029
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ceftazidime + avibactam in Klebsiella pneumoniae infection and Pseudomonas aeruginosa infection (2 arms). Primary endpoint: Microbiological success rate at 28 days. Started Aug 2025; status: recruiting.
02
Drugs
ceftazidime + avibactam
03
Conditions
Klebsiella pneumoniae infectionPseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT06811727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06811727.